The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | Current status of transplantation for myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, gives an update on transplantation for primary and secondary myelofibrosis (MF). Hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment strategy for MF. However, it is associated with a high mortality and morbidity and very few patients undergo HSCT. Whilst an increasing body of evidence is showing that this therapy can be used to treat elderly patients, it remains important to select patients that are suitable for transplant and improve transplantation outcomes. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
